NeuroIMAGE III * a follow-up study of an integrated DNA-cognition-MRI-phenotype cohort

NeuroIMAGE III * a follow-up study of an integrated DNA-cognition-MRI-phenotype cohort - NeuroIMAGE follow-up

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON37161

Enrollment

600

Registered

2013-04-09

Start date

2013-02-01

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention-Deficit Hyperactivity Disorder

Interventions

None listed

Eligibility

Age

12 Years to 99 Years

Inclusion criteria

Inclusion criteria: Participation in previous IMAGE and NeuroIMAGE investigation. Inclusion at start of first investigation (IMAGE): - ADHD-group: combined ADHD diagnosis - control group: no ADHD diagnosis, no ADHD in family for the last 2 generations - at least 1 sibling - caucasian family for 2 generations

Exclusion criteria

Exclusion criteria: - not willing to give informed consent - not willing to give permission that the general practitioner is informed in case of incidental findings

Design outcomes

Primary

Measure	Time frame
Phenotyping will occur according to the procedures of the previous measurement and includes questionnaires and a semi-structured interview to determine the presence and severity of ADHD and comorbid disorders. These will be the primary outcome measures in most analyses. The main predictors are: 1) Various MRI measures. The MRI scan consists of a 90-minute session (structural MRI, resting state, DTI, and fMRI (stop-task, reward-task, and a spatial working memory task)). Furthermore, an MRS session is included to measure levels of glutamate in the prefrontal cortex. 2) Outside the scanner, various additional cognitive tasks are administered (cognitive flexibility, verbal and visuo-spatial working memory, time reproduction, motor timing, motor control, intelligence, and positive and negative reward). 3) A blood sample will be acquired via a venipuncture to investigate biomarkers, gene expression and epigenetics.	—

Measure

Time frame

Phenotyping will occur according to the procedures of the previous measurement and includes questionnaires and a semi-structured interview to determine the presence and severity of ADHD and comorbid disorders. These will be the primary outcome measures in most analyses. The main predictors are: 1) Various MRI measures. The MRI scan consists of a 90-minute session (structural MRI, resting state, DTI, and fMRI (stop-task, reward-task, and a spatial working memory task)). Furthermore, an MRS session is included to measure levels of glutamate in the prefrontal cortex. 2) Outside the scanner, various additional cognitive tasks are administered (cognitive flexibility, verbal and visuo-spatial working memory, time reproduction, motor timing, motor control, intelligence, and positive and negative reward). 3) A blood sample will be acquired via a venipuncture to investigate biomarkers, gene expression and epigenetics.

—

Countries

Netherlands

Outcome results